Short Interest in Plus Therapeutics, Inc. (NASDAQ:PSTV) Rises By 51.0%

Plus Therapeutics, Inc. (NASDAQ:PSTV) was the recipient of a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 52,700 shares, an increase of 51.0% from the August 31st total of 34,900 shares. Based on an average daily trading volume, of 54,300 shares, the short-interest ratio is currently 1.0 days. Currently, 0.9% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Ascendiant Capital Markets decreased their price target on Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of Plus Therapeutics in a report on Friday, August 16th.

Plus Therapeutics Stock Up 20.1 %

Shares of PSTV stock traded up $0.31 during trading hours on Friday, hitting $1.85. 370,240 shares of the company’s stock were exchanged, compared to its average volume of 56,610. The firm has a market cap of $10.55 million, a P/E ratio of -0.60 and a beta of 0.65. The firm has a 50 day moving average of $1.54 and a two-hundred day moving average of $1.77. Plus Therapeutics has a fifty-two week low of $0.97 and a fifty-two week high of $2.78.

Plus Therapeutics (NASDAQ:PSTV) last announced its earnings results on Wednesday, August 14th. The company reported ($0.71) earnings per share for the quarter. The business had revenue of $1.28 million for the quarter. Plus Therapeutics had a negative return on equity of 805.57% and a negative net margin of 240.15%. On average, equities analysts forecast that Plus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Plus Therapeutics stock. AIGH Capital Management LLC acquired a new stake in Plus Therapeutics, Inc. (NASDAQ:PSTV) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned about 9.98% of Plus Therapeutics as of its most recent filing with the SEC. Institutional investors own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.